Pharmacyclics | search
Click here to view Pharmacyclics news from 60+ newspapers.
Bookmark or Share- Pharmacyclics’ ‘miracle cure’: A cancer drug saves a biotech companyPharmacyclics’ little-known chemical, now a drug called Imbruvica, sent company shares soaring from $2 to $261.25 in one of the largest acquisitions in Silicon Valley history, when pharma giant...
- This Legendary Billionaire Biotech Investor Has Remained A ... - ForbesPharmacyclics’ trial drug would go on to become Imbruvica, a game-changing medicine for CLL patients. Pharmacyclics and its one amazing drug would end up being sold for $21 billion, or $261.25...
- PharmacyclicsPharmacyclics is an AbbVie company based in the Bay Area, California. Our charge is to help people impacted by cancer and immune-mediated diseases by focusing on the development of safe and effective treatment options.
- Areas of Study - PharmacyclicsLYM3003, SPARKLE. The purpose of this Phase 3, randomized, open-label study is to evaluate the safety and efficacy of ibrutinib in pediatric and young adult patients with relapsed or refractory mature B-cell non-Hodgkin lymphoma and is set up to be conducted in two parts.
- The Wild Story Behind A Promising Experimental Cancer Drug - ForbesToday, Pharmacyclics is a $5.3B company, a value attributable largely to its promising lead compound, ibrutinib, currently in late clinical development for chronic lymphocytic leukemia (CLL) and...
More
